Top stories in endocrinology: Europe, FDA reach different conclusions on SGLT inhibitors for type 1 diabetes, chemicals replacing BPA in plastics may increase childhood obesity risk

Among the top stories in endocrinology last week were an analysis of the FDA rejecting two oral SGLT inhibitors for the treatment of type 1 diabetes that the European Commission approved earlier this year and a study that found chemicals replacing BPA in plastics and cans increased childhood obesity risk.

Other highlights included the FDA approving the first nasal glucagon powder for the emergency treatment of severe hypoglycemia, a study that found the cumulative incidence rate for pancreatic cancer increased with fasting glucose level regardless of the presence of diabetes and a study that found brown fat may increase type 2 diabetes risk in adolescents.

Europe embraces, FDA rejects use of SGLT inhibitors for type 1 diabetes

In the spring, the European Commission approved two non-insulin oral agents for use as adjuncts to insulin for adults with type 1 diabetes: dapagliflozin, an SGLT2 inhibitor previously approved for type 2 diabetes, and sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. Read more.

Chemicals replacing BPA in plastics, cans increase childhood obesity risk

Children with greater levels of the endocrine-disrupting chemicals bisphenol S and bisphenol F in their urine are more likely to have obesity when compared with children with lower levels of the chemicals, according to findings published in the Journal of the Endocrine Society. Read more.

FDA approves first nasal glucagon powder for severe hypoglycemia

The FDA approved the first nasal glucagon powder for the emergency treatment of severe hypoglycemia in children and adults with diabetes, according to an agency press release. Read more.

Risk for pancreatic cancer rises with fasting glucose, regardless of diabetes status

In a large cohort of Korean adults, the cumulative incidence rate for pancreatic cancer increased with fasting glucose level, even in people without diabetes, according to a database analysis published in The Journal of Clinical Endocrinology & Metabolism. Read more.

Brown fat may influence type 2 diabetes risk in teens

A positive association observed between brown adipose tissue and glucose tolerance in a cohort of adolescents with overweight or obesity suggests brown adipose tissue could play a role in glucose metabolism, potentially influencing the risk for developing type 2 diabetes, according to findings published in Pediatric Obesity. Read more.